Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: A multicenter placebo-controlled trial

Spotswood L. Spruance, Jeffery Stewart, Donna J. Freeman, Vernon J. Brightman, Jack L. Cox, Gay Wenerstrom, Mark B. McKeough, Nathaniel H. Rowe

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

In a double-blind, randomized, patient-initiated treatment study at five medical centers, 301 immunocompetent patients experiencing a recurrence of herpes labialis were treated with topical 15% idoxuridine (IDU) in dimethyl sulfoxide (DMSO), 80% DMSO control solution, or 2% DMSO control solution. IDU did not prevent the development of lesions but significantly accelerated lesion resolution in comparison with the combined control groups. For the total population, the mean duration of pain was reduced by 1.3 days (35%, P = .01) and the mean healing time to loss of crust by 1.7 days (21%, P = .004). Analysis of subpopulations revealed that the beneficial activity of the treatment was concentrated among the patients who began treatment in the prodrome or erythema lesion stage. For these patients, the mean duration of pain was reduced by 1.8 days (42%, P = .08) and the mean healing time to loss of crust by 3.3 days (38%, P <.001). If only patients with classic herpes lesions (vesicle, ulcer, or crust formation) were considered, there was a greater drug effect on the duration of pain (reduction by 2.6 days, 49%; P = .03) and the mean healing time to normal skin was significantly shortened (reduction by 2.3 days, 23%; P = .004). Adverse reactions to the medication were minimal.

Original languageEnglish (US)
Pages (from-to)191-197
Number of pages7
JournalJournal of Infectious Diseases
Volume161
Issue number2
StatePublished - Feb 1990
Externally publishedYes

Fingerprint

Herpes Labialis
Idoxuridine
Herpes Simplex
Dimethyl Sulfoxide
Placebos
Pain
Erythema
Ulcer
Therapeutics
Recurrence
Control Groups
Skin
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Spruance, S. L., Stewart, J., Freeman, D. J., Brightman, V. J., Cox, J. L., Wenerstrom, G., ... Rowe, N. H. (1990). Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: A multicenter placebo-controlled trial. Journal of Infectious Diseases, 161(2), 191-197.

Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis : A multicenter placebo-controlled trial. / Spruance, Spotswood L.; Stewart, Jeffery; Freeman, Donna J.; Brightman, Vernon J.; Cox, Jack L.; Wenerstrom, Gay; McKeough, Mark B.; Rowe, Nathaniel H.

In: Journal of Infectious Diseases, Vol. 161, No. 2, 02.1990, p. 191-197.

Research output: Contribution to journalArticle

Spruance, SL, Stewart, J, Freeman, DJ, Brightman, VJ, Cox, JL, Wenerstrom, G, McKeough, MB & Rowe, NH 1990, 'Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: A multicenter placebo-controlled trial', Journal of Infectious Diseases, vol. 161, no. 2, pp. 191-197.
Spruance, Spotswood L. ; Stewart, Jeffery ; Freeman, Donna J. ; Brightman, Vernon J. ; Cox, Jack L. ; Wenerstrom, Gay ; McKeough, Mark B. ; Rowe, Nathaniel H. / Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis : A multicenter placebo-controlled trial. In: Journal of Infectious Diseases. 1990 ; Vol. 161, No. 2. pp. 191-197.
@article{6b63b77f26454fb786925b2e2e1112fa,
title = "Early application of topical 15{\%} idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: A multicenter placebo-controlled trial",
abstract = "In a double-blind, randomized, patient-initiated treatment study at five medical centers, 301 immunocompetent patients experiencing a recurrence of herpes labialis were treated with topical 15{\%} idoxuridine (IDU) in dimethyl sulfoxide (DMSO), 80{\%} DMSO control solution, or 2{\%} DMSO control solution. IDU did not prevent the development of lesions but significantly accelerated lesion resolution in comparison with the combined control groups. For the total population, the mean duration of pain was reduced by 1.3 days (35{\%}, P = .01) and the mean healing time to loss of crust by 1.7 days (21{\%}, P = .004). Analysis of subpopulations revealed that the beneficial activity of the treatment was concentrated among the patients who began treatment in the prodrome or erythema lesion stage. For these patients, the mean duration of pain was reduced by 1.8 days (42{\%}, P = .08) and the mean healing time to loss of crust by 3.3 days (38{\%}, P <.001). If only patients with classic herpes lesions (vesicle, ulcer, or crust formation) were considered, there was a greater drug effect on the duration of pain (reduction by 2.6 days, 49{\%}; P = .03) and the mean healing time to normal skin was significantly shortened (reduction by 2.3 days, 23{\%}; P = .004). Adverse reactions to the medication were minimal.",
author = "Spruance, {Spotswood L.} and Jeffery Stewart and Freeman, {Donna J.} and Brightman, {Vernon J.} and Cox, {Jack L.} and Gay Wenerstrom and McKeough, {Mark B.} and Rowe, {Nathaniel H.}",
year = "1990",
month = "2",
language = "English (US)",
volume = "161",
pages = "191--197",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis

T2 - A multicenter placebo-controlled trial

AU - Spruance, Spotswood L.

AU - Stewart, Jeffery

AU - Freeman, Donna J.

AU - Brightman, Vernon J.

AU - Cox, Jack L.

AU - Wenerstrom, Gay

AU - McKeough, Mark B.

AU - Rowe, Nathaniel H.

PY - 1990/2

Y1 - 1990/2

N2 - In a double-blind, randomized, patient-initiated treatment study at five medical centers, 301 immunocompetent patients experiencing a recurrence of herpes labialis were treated with topical 15% idoxuridine (IDU) in dimethyl sulfoxide (DMSO), 80% DMSO control solution, or 2% DMSO control solution. IDU did not prevent the development of lesions but significantly accelerated lesion resolution in comparison with the combined control groups. For the total population, the mean duration of pain was reduced by 1.3 days (35%, P = .01) and the mean healing time to loss of crust by 1.7 days (21%, P = .004). Analysis of subpopulations revealed that the beneficial activity of the treatment was concentrated among the patients who began treatment in the prodrome or erythema lesion stage. For these patients, the mean duration of pain was reduced by 1.8 days (42%, P = .08) and the mean healing time to loss of crust by 3.3 days (38%, P <.001). If only patients with classic herpes lesions (vesicle, ulcer, or crust formation) were considered, there was a greater drug effect on the duration of pain (reduction by 2.6 days, 49%; P = .03) and the mean healing time to normal skin was significantly shortened (reduction by 2.3 days, 23%; P = .004). Adverse reactions to the medication were minimal.

AB - In a double-blind, randomized, patient-initiated treatment study at five medical centers, 301 immunocompetent patients experiencing a recurrence of herpes labialis were treated with topical 15% idoxuridine (IDU) in dimethyl sulfoxide (DMSO), 80% DMSO control solution, or 2% DMSO control solution. IDU did not prevent the development of lesions but significantly accelerated lesion resolution in comparison with the combined control groups. For the total population, the mean duration of pain was reduced by 1.3 days (35%, P = .01) and the mean healing time to loss of crust by 1.7 days (21%, P = .004). Analysis of subpopulations revealed that the beneficial activity of the treatment was concentrated among the patients who began treatment in the prodrome or erythema lesion stage. For these patients, the mean duration of pain was reduced by 1.8 days (42%, P = .08) and the mean healing time to loss of crust by 3.3 days (38%, P <.001). If only patients with classic herpes lesions (vesicle, ulcer, or crust formation) were considered, there was a greater drug effect on the duration of pain (reduction by 2.6 days, 49%; P = .03) and the mean healing time to normal skin was significantly shortened (reduction by 2.3 days, 23%; P = .004). Adverse reactions to the medication were minimal.

UR - http://www.scopus.com/inward/record.url?scp=0025019789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025019789&partnerID=8YFLogxK

M3 - Article

C2 - 2153736

AN - SCOPUS:0025019789

VL - 161

SP - 191

EP - 197

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -